Ahmet ALACACIOĞLU, Eda ÜLGER, Umut VAROL, İbrahim YILDIZ, Tarık SALMAN, Vedat BAYOĞLU, Ahmet DİRİCAN, Murat AKYOL, Yaşar YILDIZ, Yüksel KÜÇÜKZEYBEK, İnci ALACACIOĞLU, Mustafa Oktay TARHAN

Premenapozal Meme Kanseri Hastasında Tamoksifenin Anksiyete, Depresyon, Yaşam Kalitesi ve Cinsel Doyum Üzerine Etkisi

AMAÇ: Bu çalışmada premenapozal meme kanserli hastalarda tamoxifenin etkilerini, anksiyete, depresyon, yaşam kalitesi ve cinsel doyumları açısından belirlemek amaçlandı. YÖNTEMLER: Adjuvan tamoxifen kullanan 67 premenapozal meme kanserli bayan çalışmaya dahil edildi ve veriler yüzyüze görüşme sırasında bir dizi formlar kullanılarak toplandı. Çalışmada, sosyo-demografik bilgi formu, Hastane Anksiyete ve Depresyon Ölçeği (HADS), Golombok-Rust Cinsel Doyum Ölçeği (GRCDÖ) ve Yaşam Kalitesi Ölçeği (EORTC-QoL-C30) uygulandı. BULGULAR: Hastaların %46.26'sında depresyon, %40.29'unda yüksek seviyede anksiyete saptandı. Fiziksel, rol, bilişsel, duygusal ve sosyal işlevsellik ve global yaşam kalitesi altskorları, anksiyete seviyeleri yüksek hastalarda düşük bulundu. Depresyon skorları yüksek olan hastalarda, fiziksel işlevsellikve global yaşam kalitesi altskorları dışındaki tüm işlevsellik skalaları istatistiksel olarak düşük bulundu. Anksiyete seviyeleri yüksek olan hastalarda, tüm GRCDÖ altskorları yüksekti. Fakat istatiksel olarak fark sadece iletişim, doyum, dokunma ve anorgasmi altskorlarında gözlemlendi. Depresyon seviyeleri yüksek olan hastalarda tüm GRCDÖ altskorları yüksekti. Fakat istatiksel olarak fark sadece iletişim, doyum, dokunma ve anorgasmi altskorlarında gözlemlendi.SONUÇ: Meme kanseri ve uzun dönemli adjuvant tedaviler, hastaların sadece klinik durumlarını değil psikososyal ve psikoseksüel durumlarını da etkilemektedir. Bu nedenle, bu durumların farkında olunması, meme kanserli hastaların yaşam kalitesini yükseltecektir.

Anahtar Kelimeler:

Depresyon, Anksiyete; Yaşam kalitesi; Cinsel doyum, Meme kanseri

Effects of Tamoxifen on Premenopausal Breast Cancer Patients in Terms of Anxiety, Depression, Quality of Life and Sexual Satisfaction

OBJECTIVE: In this study, we aimed to determine the effects of tamoxifen on premenopausal breast cancer patients in terms of anxiety, depression, quality of life (QoL) and sexual satisfaction.METHODS: Sixty-seven premenopausal breast cancer women using adjuvant tamoxifen were participated in the study and the data were collected using a series of forms completed during face-to-face interviews. The form that consists of socio-demographic characteristics of the pateints, the Hospital Anxiety and Depression Scale (HADS), Golombok-Rust Inventory of Sexual Satisfaction (GRISS) and European Organization for Research on Treatment of Cancer Questionnaires Quality of Life-C30 (EORTC-QoL-C30) were applied to the participants. RESULTS: We determined that 46.26% of the patients had depression and 40.29% had high anxiety levels. Physical, role, cognitive, emotional and social functioning and global QoL subscores were also found to be low in patients whose anxiety levels were high. In patients whose depression scores were high, all the functioning scales, except physical functioning scale and global QoL subscores of EORTC-QLQ-C30 were found statistically significantly low. All the GRISS subscores were higher in the patients whose anxiety levels were high. However, statistical significance was observed only in the communication, satisfaction, touch and anorgasmi subscores. All the GRISS subscores were higher in the patients who had high depression level. But the statistical significance was found only in communication, satisfaction, touch and anorgasmi subscores. CONCLUSION: Breast cancer and its long-term adjuvant treatments affect not only the patients' clinical status but also their psychosocial and psychosexual aspects. Therefore, being aware of these aspects and management of them may increase the quality of life of breast cancer patients.

Keywords:

Depression, Anxiety; Sexual satisfaction; Quality of life; Breast cancer,

PDF

___

Breast cancer resource center facts and figures, 2001. American Cancer Society Web site. Avaliable at http://www.cancer .org.Accessed July 31, 2001
Pandey M, Sarita GP, Devi N, et al. Distress, anxiety and depression in cancer patients undergoing chemotherapy. World J Surg Oncol 2006;4:68
Brem S, Kumar NB. Management of treatment- related cancer:current strategies and future directions. Clin J Oncol Nurs 2011;15:63-71 patients with breast
Epplein M, Zheng Y, Zheng W et al. Quality of life after breast cancer diagnosis and survival . J Clin Oncol 2011;29;406-12
Derogatis LR, Morrow GR, Fetting J. The prevelance of psychiatric disorder among cancer patients. JAMA 1983;297:751-5
Trask P. Assessment of depression in cancer patients. Journal of the National Cancer Institute: Monographs 2004;32:80-92
Stark D, Kiely M, Smith A, Velikova G, House A, Selby P. Anxiety disorders in cancer patients: Their nature, associations and relation to quality of life. Journal of Clinical Oncology 2002;14:3137-48
Pumo V, Milone G, Iacono M, et al. Psychological and sexual disorders in long-term breast cancer survivors. Cancer Manag Res 2012;4:61-5
Badger T, Sergin C, Dorros SM, Meek P, Lopez AM. Depression and anxiety in women with breast cancer and their partners. Nurs Res 2007;56:44-53
Avis NE, Crawford S, Manuel J. Quality of life among younger women with breast cancer. J Clin Oncol 2005;23:3322-30
Wenzel LB, Fairclough DL, Brady MJ, et al. Age- related differences in the quality of life of breast carcinoma 1999;86:1768-74 treatment. Cancer
Schou I, Ekeberg O, Ruland CM, Sandvik L, Karesen R. Pessimism as a predictor of emotional morbidity one year following breast cancer surgery. Psycho- Oncology 2004;13:309-20
Early Breast Cancer Trialists Group Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996;348:1189-96
Early Breast Cancer Trialists Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67
Jonat W, Kaufmann M, Sauerbrei R, et al. For the Zoladex Early Breast Cancer Collaborative Research Assosiationgroup. cyclophosphamide and fluorouracil as adjuvant therapy in premenopausal patients with node-pozitive breast cancer. J Clin Oncol 2002;20:4628-35 versus
Boccardo F, Bruzzi A, Rubagtti G, et al. Estrogen- like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 1981;38:281-5
Ferrazzi E, Cartei G, Mattarazzo R, et al: Oestrogen- like effect of tamoxifen on vaginal epithelium. BMJ 1977;1:1351-2
Thors CL, Broeckel JA, Jacobsen PB. Sexual functioning in brest cancer survivors. Cancer Control 2001;8:442-8
Mortimer JE, Boucher, L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of Tamoxifen on Sexual Functioning in Patients With Breast Cancer. J Clin Oncol 1999;17:1488-92
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361- 70
Aydemir Ö. Hastane Anksiyete ve Depresyon Ölçeği Türkçe formunun geçerlilik ve güvenilirlik çalışması. Türk Psikiyatri Dergisi 1997;8:280-7
Rust J, Golombok S. The GRISS: a psychometric instrument for the assessment of sexual dysfunc-tion. Arch Sex Behav 1986;15:157-65
Tuğrul C, Öztan N, Kabakçı E. Golombok-Rust Cinsel Doyum Ölçeği’nin standardizasyon çalışması. Türk Psikiyatri Dergisi 1993;4:83-8
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-c30: a quality of life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 1993;85:365-76
Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual, In third edition ed, 2001
Beser N, Öz F. Kemoterapi alan lenfomalı hastaların anksiyete-depresyon düzeyleri ve yaşam kalitesi. C.Ü. Hemşirelik Yüksekokulu Dergisi 2003;7:47-58
Palson M-BE, Norberg A. Breast cancer experiences of nursing care with the focus on emotional support: The implication of a nursing intervention. Journal of Advanced Nursing 1995;21:277-85
Henson HK. Breast Cancer and Sexuality. Sexuality and Disability 2002;20:261-75
Lim CC, Devi MK, Ang E. Anxiety in women with breast cancer undergoing treatment: a systematic review. Int J Evid Based Healthc 2011;9:215-35
Thewes B, Meiser B, Duric VM, et al. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol 2005;6:581-8
Fallowfield LJ, Leaity S, Howell A, et al. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT B. Breast Cancer Res Treat 1999;55:189-99
Anllo LM. Sexual life after breast cancer. J Sex Marital Ther 2000;26:241-8
Simes R, Coates A. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? Monogr Natl Cancer Instit 2001;30:146-52
Schover LR, Yetman RJ, Tuason LJ, et al. Partial mastectomy and breast reconstruction:Acomparison of their effects on psychosocial adjustment, body image, and sexuality. Cancer 1995;75:54-64
Young-McCaughan S. Sexual functioning in women with breast cancer after treatment with adjuvant therapy. Cancer Nurs 1996;19:308-19
Ganz PA, Rowland JH, Meyerowitz BE, et al. Impact of different adjuvant therapy stragies on quality of life in breast cancer survivors. Recent Results Cancer Res 1998;152:396-411